ES2977332T3 - Combinación que comprende un antagonista de il-4r, un corticosteroide y un agonista beta2 adrenérgico de acción prolongada para el tratamiento de asma - Google Patents

Combinación que comprende un antagonista de il-4r, un corticosteroide y un agonista beta2 adrenérgico de acción prolongada para el tratamiento de asma Download PDF

Info

Publication number
ES2977332T3
ES2977332T3 ES21191120T ES21191120T ES2977332T3 ES 2977332 T3 ES2977332 T3 ES 2977332T3 ES 21191120 T ES21191120 T ES 21191120T ES 21191120 T ES21191120 T ES 21191120T ES 2977332 T3 ES2977332 T3 ES 2977332T3
Authority
ES
Spain
Prior art keywords
antibody
antigen
binding fragment
asthma
ics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21191120T
Other languages
English (en)
Spanish (es)
Inventor
Gianluca Pirozzi
Franck Skobieranda
Yongtao Li
Neil Graham
Steven P Weinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51570453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2977332(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Application granted granted Critical
Publication of ES2977332T3 publication Critical patent/ES2977332T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES21191120T 2014-02-21 2015-02-20 Combinación que comprende un antagonista de il-4r, un corticosteroide y un agonista beta2 adrenérgico de acción prolongada para el tratamiento de asma Active ES2977332T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461943019P 2014-02-21 2014-02-21
EP14306413 2014-09-15
US201462077669P 2014-11-10 2014-11-10

Publications (1)

Publication Number Publication Date
ES2977332T3 true ES2977332T3 (es) 2024-08-22

Family

ID=51570453

Family Applications (2)

Application Number Title Priority Date Filing Date
ES21191120T Active ES2977332T3 (es) 2014-02-21 2015-02-20 Combinación que comprende un antagonista de il-4r, un corticosteroide y un agonista beta2 adrenérgico de acción prolongada para el tratamiento de asma
ES15708991T Active ES2897631T3 (es) 2014-02-21 2015-02-20 Procedimientos para tratar o prevenir el asma mediante la administración de un antagonista de IL-4R

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15708991T Active ES2897631T3 (es) 2014-02-21 2015-02-20 Procedimientos para tratar o prevenir el asma mediante la administración de un antagonista de IL-4R

Country Status (15)

Country Link
US (3) US10137193B2 (enExample)
EP (3) EP3107575B1 (enExample)
JP (3) JP6673840B2 (enExample)
KR (4) KR20230167770A (enExample)
CN (1) CN106232140A (enExample)
AU (3) AU2015218808B2 (enExample)
CA (1) CA2940295A1 (enExample)
ES (2) ES2977332T3 (enExample)
HU (1) HUE065844T2 (enExample)
IL (1) IL315136A (enExample)
MX (2) MX384192B (enExample)
PL (2) PL3973987T3 (enExample)
PT (2) PT3107575T (enExample)
RU (1) RU2713406C2 (enExample)
WO (1) WO2015127229A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
KR102307248B1 (ko) 2012-08-21 2021-10-01 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
NZ630178A (en) 2012-09-07 2017-06-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
MX368068B (es) 2013-06-21 2019-09-18 Sanofi Biotechnology Antagonista de il-4r para usarse para tratar la poliposis nasal.
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
LT3838271T (lt) 2013-07-12 2025-11-10 Padidėjusio eozinofilų ir (arba) bazofilų kiekio gydymas
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
KR20160120735A (ko) 2014-02-28 2016-10-18 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
CA2967602C (en) 2014-11-14 2024-09-24 Regeneron Pharmaceuticals, Inc. METHODS OF TREATMENT OF CHRONIC SINUSITIS WITH NASAL POLYPOSIS BY ADMINISTRATION OF AN IL-4R ANTAGONIST
US20180056018A1 (en) * 2016-08-31 2018-03-01 Cephalon, Inc. Inhalation Systems, Devices and Methods
US11771743B2 (en) * 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
JP7164530B2 (ja) 2016-09-22 2022-11-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
TWI857389B (zh) * 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
KR102751957B1 (ko) * 2017-04-13 2025-01-09 리제너론 파마슈티칼스 인코포레이티드 Il33 및 il1rl1을 코딩하는 유전자에서의 위험 대립유전자를 갖는 환자에서의 폐 질환의 치료 및 저해
EP3645010A4 (en) 2017-06-27 2021-03-24 Ohio State Innovation Foundation NUCLEOTIDE-BASED THERAPY FOR ASTHMA
EP3645009A4 (en) 2017-06-27 2021-03-31 The Ohio State Innovation Foundation LIPONUCLEOTIDE THERAPY FOR COPD
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
EP4344706A3 (en) 2017-10-30 2024-05-22 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
CN120227453A (zh) 2018-05-13 2025-07-01 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
MY202673A (en) * 2018-07-10 2024-05-14 Regeneron Pharma Modifying binding molecules to minimize pre-existing interactions
CN110872349A (zh) * 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
CN111514292B (zh) 2018-12-25 2023-06-20 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
CA3125067A1 (en) * 2018-12-27 2020-07-02 Akeso Biopharma, Inc. Antibody against human il-4ra and use thereof
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
SG11202111255YA (en) * 2019-05-01 2021-11-29 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
KR20220042217A (ko) 2019-08-05 2022-04-04 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
KR20220110829A (ko) * 2019-12-09 2022-08-09 사노피 바이오테크놀로지 디지털 식별된 il-4/il-13 관련 장애의 치료 방법
CN113797331A (zh) * 2020-06-16 2021-12-17 三生国健药业（上海）股份有限公司 一种稳定的抗IL-4Rα单克隆抗体液体制剂
AU2021322255A1 (en) * 2020-08-05 2023-02-23 Areteia Therapeutics, Inc. Use of dexpramipexole for the treatment of moderate to severe asthma
CA3194111A1 (en) * 2020-10-05 2022-04-14 Christine XU Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
CN119174816A (zh) * 2021-08-26 2024-12-24 正大天晴药业集团股份有限公司 抗il4r抗体的药物组合物及其用途
CN117368487A (zh) * 2023-09-28 2024-01-09 首都医科大学附属北京同仁医院 一种利用局部IgE预测或评估奥马珠单抗在治疗复发性鼻息肉中疗效的方法和应用
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
NZ547588A (en) 2003-11-07 2009-05-31 Immunex Corp Antibodies that bind interleukin-4 receptor
CA2550933A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
AU2005219837A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
AU2007209202A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind IL-4 and/or IL-13
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
DK2769992T3 (da) 2006-10-02 2021-03-22 Regeneron Pharma Humane antistoffer med høj affinitet for human IL-4-receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2604628A3 (en) * 2007-12-21 2013-08-21 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4R) - 173
CA2748712A1 (en) 2008-12-01 2010-06-10 Children's Hospital Medical Center Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
EP2414520A2 (en) 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
WO2011156000A2 (en) * 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
DK2627673T3 (da) * 2010-10-15 2017-11-06 Medimmune Ltd Terapier til forbedring af lungefunktionen
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
KR20140097217A (ko) * 2011-11-01 2014-08-06 메디뮨 엘엘씨 급성 천식 악화의 빈도 및 중증도를 감소시키는 방법
KR102307248B1 (ko) 2012-08-21 2021-10-01 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
NZ630178A (en) 2012-09-07 2017-06-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
MX368068B (es) 2013-06-21 2019-09-18 Sanofi Biotechnology Antagonista de il-4r para usarse para tratar la poliposis nasal.
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CA2967602C (en) 2014-11-14 2024-09-24 Regeneron Pharmaceuticals, Inc. METHODS OF TREATMENT OF CHRONIC SINUSITIS WITH NASAL POLYPOSIS BY ADMINISTRATION OF AN IL-4R ANTAGONIST
EP4344706A3 (en) * 2017-10-30 2024-05-22 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
CA3194111A1 (en) 2020-10-05 2022-04-14 Christine XU Methods for treating asthma in pediatric subjects by administering an il-4r antagonist

Also Published As

Publication number Publication date
JP7636487B2 (ja) 2025-02-26
AU2020277191B2 (en) 2024-05-16
PT3973987T (pt) 2024-04-01
IL315136A (en) 2024-10-01
MX2016010854A (es) 2017-01-05
MX2021008113A (es) 2021-10-13
WO2015127229A1 (en) 2015-08-27
US20210322546A1 (en) 2021-10-21
EP3973987B1 (en) 2024-01-10
PL3973987T3 (pl) 2024-06-24
AU2020277191A1 (en) 2020-12-24
CN106232140A (zh) 2016-12-14
KR20160113733A (ko) 2016-09-30
JP2025072593A (ja) 2025-05-09
RU2016136364A3 (enExample) 2018-10-11
AU2015218808B2 (en) 2020-09-24
KR102368450B1 (ko) 2022-02-28
JP2023162343A (ja) 2023-11-08
PL3107575T3 (pl) 2022-01-17
EP4382164A3 (en) 2024-08-07
EP3107575A1 (en) 2016-12-28
JP2017507139A (ja) 2017-03-16
KR20250154567A (ko) 2025-10-28
RU2016136364A (ru) 2018-03-22
KR20230167770A (ko) 2023-12-11
PT3107575T (pt) 2021-11-18
MX384192B (es) 2025-03-14
AU2015218808A1 (en) 2016-09-22
RU2713406C2 (ru) 2020-02-05
EP4382164A2 (en) 2024-06-12
US10137193B2 (en) 2018-11-27
EP3973987A1 (en) 2022-03-30
EP3107575B1 (en) 2021-09-01
CA2940295A1 (en) 2015-08-27
AU2024203849A1 (en) 2024-06-27
JP6673840B2 (ja) 2020-03-25
KR20220029765A (ko) 2022-03-08
ES2897631T3 (es) 2022-03-02
HUE065844T2 (hu) 2024-06-28
US20190125865A1 (en) 2019-05-02
US20150246119A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
ES2977332T3 (es) Combinación que comprende un antagonista de il-4r, un corticosteroide y un agonista beta2 adrenérgico de acción prolongada para el tratamiento de asma
US20240199751A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
CN111437387B (zh) 通过施用il-4r拮抗剂治疗鼻息肉症的方法
KR20200081429A (ko) Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
CN107206073A (zh) 通过施用il‑4r拮抗剂用于治疗伴随鼻息肉的慢性鼻窦炎的方法
CN114786775A (zh) 通过施用il-33拮抗剂治疗copd的方法
JP7343547B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
HK40110800A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40070002B (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
HK40070002A (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
US20250388685A1 (en) Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
HK1231767B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
TW201907950A (zh) 投與ｉｌ－４ｒ拮抗劑以治療或預防氣喘之方法